No, what I'm saying is the people who authored the study are doing a disservice by stating they feel the kids got better due to Remestemcell. Or that they rapidly got better after remestemcell, and that likely means it works.
That's not good science. And they're on MSBs payroll. The study is neat, but there are no conclusions to draw.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-95
-
- There are more pages in this discussion • 329 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20471 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 52582 | 3 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |